A Phase 2a Multicenter Open-label Study to Evaluate the Safety and Efficacy of OnabotulinumtoxinA X in Subjects With Glabellar Lines
Latest Information Update: 15 Jun 2023
At a glance
- Drugs Botulinum-Toxin-A (Primary)
- Indications Glabellar lines
- Focus Adverse reactions; Proof of concept
- Sponsors Allergan
- 27 Jul 2022 Status changed from active, no longer recruiting to completed.
- 26 Jan 2022 Planned End Date changed from 13 Jun 2022 to 13 Jul 2022.
- 26 Jan 2022 Planned primary completion date changed from 13 Jun 2022 to 13 Jul 2022.